好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Seizure-Free Rates in Patients Receiving Long-Term Open-Label Ezogabine (Retigabine) 600-1200mg/Day
Epilepsy
(-)
050
Authors/Disclosures
Bassel W. Abou-Khalil, MD, FAAN (Vanderbilt University) The institution of Dr. Abou-Khalil has received research support from Cerevel. The institution of Dr. Abou-Khalil has received research support from Xenon. The institution of Dr. Abou-Khalil has received research support from Otsuka. The institution of Dr. Abou-Khalil has received research support from UCB. The institution of Dr. Abou-Khalil has received research support from SK LIfe Science. The institution of Dr. Abou-Khalil has received research support from Neuroelectrics.
Martin Brodie Martin Brodie has nothing to disclose.
No disclosure on file
No disclosure on file
No disclosure on file
Kevan E. VanLandingham, MD, PhD, FAAN (US Food and Drug Administration) Dr. VanLandingham has received personal compensation for serving as an employee of Greenwich Biosciences. Dr. VanLandingham has received stock or an ownership interest from Greenwich Biosciences.
No disclosure on file
David Laplaud No disclosure on file